Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment

por Zhou, Shiyuan, Zhai, Yingying, Yan, Lingzhi, Shi, Xiaolan, Shang, Jingjing, Wu, Depei, Fu, Chengcheng, Jin, Song
Publicado 2023

Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma

por Ping, Nana, Qu, Changju, Li, Mengyun, Kang, Liqing, Kong, Danqin, Chen, Xiaochen, Wu, Qian, Xia, Fan, Yu, Lei, Yao, Hong, Yan, Lingzhi, Wu, Depei, Jin, Zhengming
Publicado 2022

Successful treatment of marrow failure after CARTs for myeloma by the infusion of cryopreserved stem cells

por Yan, Lingzhi, Shang, Jingjing, Shi, Xiaolan, Kang, Huizhu, Liu, Wei, Xu, Nan, Liu, Yong, Chen, Guanghua, Kang, Liqing, Gong, Feiran, Tang, Fang, Yu, Lei, Wu, Depei, Fu, Chengcheng
Publicado 2019

The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients

por You, Hongying, Jin, Song, Wu, Chunxiao, Wang, Qingqing, Yan, Shuang, Yao, Weiqin, Shi, Xiaolan, Shang, Jingjing, Yan, Lingzhi, Yao, Ying, Wang, Jing, Wang, Panfeng, Pan, Jinlan, Wu, Depei, Fu, Chengcheng
Publicado 2022

A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

por An, Gang, Zhou, Daobin, Cheng, Shu, Zhou, Keshu, Li, Jianyong, Zhou, Jianfeng, Xie, Liping, Jin, Jie, Zhong, Liye, Yan, Lingzhi, Guo, Haiyi, Du, Chenmu, Zhong, Jinhua, Yu, Yiling, Wu, Binghao, Qiu, Lugui
Publicado 2021

The prognostic significance of circulating plasma cells in newly diagnosed multiple myeloma patients

por Yao, Weiqin, Yang, Haifei, You, Hongying, Shang, Jingjing, Zhai, Yingying, Yan, Zhi, Yan, Shuang, Shi, Xiaolan, Yao, Ying, Wang, Jing, Wang, Panfeng, Xu, Yun, Jin, Song, Yan, Lingzhi, Wu, Depei, Fu, Chengcheng
Publicado 2023

Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma

por Yan, Lingzhi, Qu, Su, Shang, Jingjing, Shi, Xiaolan, Kang, Liqing, Xu, Nan, Zhu, Mingqing, Zhou, Jin, Jin, Song, Yao, Weiqin, Yao, Ying, Chen, Guanghua, Chang, Huirong, Zhu, Xiaming, Yu, Lei, Wu, Depei, Fu, Chengcheng
Publicado 2020

Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells

por Tan, Jingwen, Jia, Yujie, Zhou, Meixia, Fu, Chengcheng, Tuhin, Israth Jahan, Ye, Jing, Monty, Masuma Akter, Xu, Nan, Kang, Liqing, Li, Minghao, Shao, Jiaqi, Fang, Xiaoyan, Zhu, Hongjia, Yan, Lingzhi, Qu, Changju, Xue, Shengli, Jin, Zhengming, Chen, Suning, Huang, Haiwen, Xu, Yang, Chen, Jia, Miao, Miao, Tang, Xiaowen, Li, Caixia, Yan, Zhiqiang, Wu, Depei, Yu, Lei
Publicado 2022

Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placeb...

por Xia, Zhongjun, Leng, Yun, Fang, Baijun, Liang, Yang, Li, Wei, Fu, Chengcheng, Yang, Linhua, Ke, Xiaoyan, Jiang, Hua, Weng, Jianyu, Liu, Li, Zhao, Yaozhong, Zhang, Xuejun, Huang, Zhongxia, Liu, Aichun, Shi, Qingzhi, Gao, Yuhuan, Chen, Xiequn, Pan, Ling, Cai, Zhen, Wang, Zhao, Wang, Yafei, Fan, Yaqun, Hou, Ming, Ma, Yigai, Hu, Jianda, Liu, Jing, Zhou, Jianfeng, Zhang, Xiaohong, Meng, Haitao, Lu, Xuzhang, Li, Fei, Ren, Hanyun, Huang, Bintao, Shao, Zonghong, Zhou, Hebing, Hu, Yu, Yang, Shifang, Zheng, Xiangjun, Wei, Peng, Pang, Hongyan, Yu, Wei, Liu, Yuzhang, Gao, Sujun, Yan, Lingzhi, Ma, Yanping, Jing, Hongmei, Du, Juan, Ling, Wei, Zhang, Jingyi, Sui, Weiwei, Wang, Fuxu, Li, Xin, Chen, Wenming
Publicado 2023